orforglipron and retatrutide Lilly oral GLP-1 phase 3 weight loss trial Eli Lilly Exec Talks New

K., Kranz, B., Wingen, A

Common Side Effects: Injection site reactions (redness, pain, swelling) Flushing and warmth, particularly facial flushing lasting 510 minutes post-injection Water retention Headaches Dizziness Increased hunger Tingling or numbness in extremities Fatigue or lethargy initially Less Common Side Effects: Nausea Joint discomfort Mood changes Anxiety Flu-like symptoms Potential Concerns: The FDA has noted concerns about increased heart rate and cardiac events associated with CJC-1295

Among the distribution channel segment, Retail Pharmacies held the largest segment accounting for 56.70% in 2024

The Perfect Packaging Balance: Price, Performance, Sustainability When it comes to GLP-1 packaging, there is no single solution

The oral Wegovy pill produced an average weight loss of 13.6% over 64 weeks, compared to roughly 15% for the injectable version over 71 weeks